8-K current report · filed Aug 4, 2026

Beam Therapeutics Inc. (BEAM) 8-K Current Report: August 4, 2026

Item EX-99.1Item 2.02BEAM overview

Short answer

Beam Therapeutics Inc. (BEAM) filed an 8-K current report with the SEC on August 4, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q2 2026 financial results announced for quarter ended June 30, 2026.

Beam Therapeutics Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 financial results announced for quarter ended June 30, 2026
  • Exhibit 99.1 contains the earnings release, the key source for revenue, cash runway and clinical spending details

Item EX-99.1 · Exhibit EX-99.1

  • BEAM-302 entered global pivotal dosing, advancing AATD toward potential accelerated approval and creating a major 2026 clinical catalyst
  • Risto-cel dosing completed in adult and adolescent BEACON patients, with updated data and potential BLA submission by year-end 2026
  • Cash, equivalents and marketable securities totaled $1.2B, with expected funding into mid-2029 including $200M Sixth Street draw
  • Second-quarter net loss widened to $122.7M, or $1.18 per share, from $102.1M, or $1.00 per share
  • BEAM-304 received FDA IND clearance, enabling Phase 1/2 testing in PKU and expanding Beam’s liver-targeted pipeline beyond AATD

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Beam Therapeutics Inc. 8-K filings

Get the next BEAM 8-K as it lands

Follow BEAM for push alerts, or ask the research agent what this filing means.